Manufacturer Discretionary Pricing: The 340B Savings Most Hospitals Never Ask For
By 340B Orphan Drug Solutions 11-10-2026 18
In many cases, the most significant savings on 340B drugs that can be obtained by hospitals are not even guaranteed by the law. These 340B drug savings become possible only when a drug manufacturer decides to provide them.
That is the reality of manufacturer discretionary pricing, and it is one of the least understood parts of the 340B Drug Pricing Program. Hospitals that never ask for it never get it.
What is 340B Discretionary Pricing?
Discretionary pricing refers to 340B pricing that a manufacturer is not legally required to provide, but chooses to offer anyway.
This definition is relevant only in one very particular context: orphan drugs. According to 42 U.S.C. § 256b(e), certain types of hospitals are exempted from mandatory 340B orphan drug pricing. These hospitals are:
- Free-standing cancer hospitals
- Critical access hospitals
- Sole community hospitals
- Rural referral centers
According to HRSA's own guidance, manufacturers are not required to provide these covered entities with orphan drugs under the 340B Program. A manufacturer may choose to offer discounts on orphan drugs to these hospitals.
That single sentence is the entire legal basis for 340B discretionary pricing.
Why This Rule Exists
This was not always settled. In 2013, HRSA issued a rule stating manufacturers had to offer 340B pricing on orphan drugs whenever those drugs were used for a non-orphan indication.
The Pharmaceutical Research and Manufacturers of America challenged that rule in federal court. A judge vacated it in 2014, and after HRSA tried again with a revised interpretive rule, a second court decision in October 2015 vacated that version too.
The outcome left manufacturers with no binding legal requirement to extend 340B pricing on orphan drugs to the four affected hospital types, for any indication. What remained was pure manufacturer discretion.
How Manufacturer Discretionary Pricing Works in Practice
From 2015 onwards, each manufacturer has gone about things differently. While some provide 340B discounts on their orphan products to certain hospitals as a standard practice, others refuse to give any such discount for any indication.
There is no single public list guaranteeing which manufacturers participate and which do not. Policies can also change over time as manufacturers reassess their own pricing strategy, sometimes without much public notice.
In other words, the policy of discretionary pricing by the drug manufacturer cannot be verified by a hospital once and for all. A drug that was entirely excluded from purchase last year can suddenly be included in the 340B program this year, and the hospital won't even realize it.
The problem of inconsistency appears for hospitals when planning a drug budget. Hospitals buying the same orphan drug from two different manufacturers receive two entirely different prices just because of one decision made by the manufacturer.
Why Orphan Drug Pricing Is Where This Matters Most
Orphan drugs are expensive. These drugs have been gaining popularity in hospital formularies. The FDA's Office of Orphan Products Development has issued thousands of orphan drug designations over the past four decades, and most of the drugs that cost the most in oncology and rare disease treatment are designated with this designation.
For hospitals covered by the orphan drug exclusion, that means the most expensive medications are excluded from 340B pricing altogether. Discretionary pricing is often the only path back to savings on these drugs.
How Hospitals Can Pursue 340B Discretionary Pricing
Acquiring Manufacturer 340B discounts for orphan drugs is not automatic. It takes proactive effort and action.
- Identify affected drugs first. Check the list of current FDA-designated orphan drugs against your formulary.
- Research manufacturer policy. Some manufacturers disclose their discretionary pricing policy; others leave it up to a query.
- Submit a formal request. Manufacturers usually want documentation confirming your covered entity status and purchasing volume.
- Track responses over time. The manufacturer that initially turns down discretionary pricing may reverse this decision at a later point.
- Load pricing correctly once secured. Discretionary agreements still need to flow through your 340B account accurately to actually generate savings.
All these steps take time, and hospital pharmacy departments are already busy enough handling routine compliance tasks.
The Cost of Not Asking
Hospitals that assume discretionary pricing is not worth pursuing make decisions by default, not by analysis. Each unwarranted discount leaves dollars on the table that would otherwise accrue indefinitely.
With the number of orphan drugs currently on formulary in hospitals, these savings can translate into a significant reduction in their drug budget. This applies especially in hospitals that have many patients with oncological or rare diseases.
Frequently Asked Questions
Q1. Is manufacturer discretionary pricing the same as the standard 340B ceiling price?
Ans: Not necessarily. The standard ceiling price is a legal requirement tied to a manufacturer's Pharmaceutical Pricing Agreement.
On the other hand, discretionary pricing on orphan drugs is voluntary. Also, it can be withdrawn or changed by the manufacturer at any time.
Q2. Can a manufacturer change its discretionary pricing decision later?
Ans: Yes. Since these agreements are voluntary rather than statutory, a manufacturer can start, stop, or modify discretionary 340B pricing on its orphan drugs at any time.
Q3. Which hospitals need to worry about discretionary pricing for orphan drugs?
Ans: This problem arises only for the four covered entities, which are freestanding cancer hospitals, critical access hospitals, sole community hospitals, and rural referral centers.
Stop Leaving Discretionary Savings Unclaimed
Discretionary pricing will never show up automatically in your 340B account. It has to be requested, tracked, and maintained.
340B Orphan Drug Solutions specializes in identifying which orphan drugs on your formulary qualify for manufacturer discretionary pricing and pursuing those agreements directly.
Contact 340B Orphan Drug Solutions today to find out how much discretionary 340B drug savings your hospital may be missing.
